{"id":"NCT01493778","sponsor":"Novo Nordisk A/S","briefTitle":"Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A","officialTitle":"Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09-17","primaryCompletion":"2017-08-16","completion":"2018-12-05","firstPosted":"2011-12-16","resultsPosted":"2018-10-30","lastUpdate":"2020-11-30"},"enrollment":60,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Congenital Bleeding Disorder","Haemophilia A"],"interventions":[{"type":"DRUG","name":"turoctocog alfa","otherNames":[]}],"arms":[{"label":"turoctocog alfa","type":"EXPERIMENTAL"}],"summary":"This trial is conducted in Asia, Europe and North America. The purpose of the trial is to evaluate the safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in previously untreated children with haemophilia A.","primaryOutcome":{"measure":"Incidence Rate of Factor VIII Inhibitors (Above or Equal to 0.6 BU (Bethesda Units)/mL) for the Main Phase of the Trial","timeFrame":"From Visit 2 (21 days after screening) to Visit 5 (50-55 exposure day)","effectByArm":[{"arm":"Turoctocog Alfa (N8): Main Phase (Preventive Treatment)","deltaMin":43.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"0 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":69,"countries":["United States","Algeria","Austria","Brazil","China","Denmark","Greece","Hong Kong","Hungary","Japan","Lithuania","Poland","Portugal","Puerto Rico","Russia","Serbia","Spain","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":60},"commonTop":["Pyrexia","Nasopharyngitis","Cough","Upper respiratory tract infection","Diarrhoea"]}}